Abstract
Dapagliflozin (Farxiga) is now approved to reduce the risk of declining kidney function, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease with or without type 2 diabetes.
Cite
CITATION STYLE
APA
Aschenbrenner, D. S. (2021). Antidiabetic Drug Approved to Reduce Risk of Kidney Disease. The American Journal of Nursing, 121(9), 25. https://doi.org/10.1097/01.NAJ.0000790624.30479.00
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free